|1.||Mehta, Rajendra G: 7 articles (09/2009 - 01/2003)|
|2.||Mehta, Rajeshwari R: 4 articles (03/2006 - 01/2003)|
|3.||Hussain-Hakimjee, Erum A: 3 articles (09/2009 - 03/2006)|
|4.||Peng, Xinjian: 3 articles (05/2007 - 03/2006)|
|5.||Jhaveri, Pavan: 1 article (05/2007)|
|6.||Wang, Sheng: 1 article (07/2006)|
|7.||Chellappan, Srikumar: 1 article (07/2006)|
|8.||Mehta, Rajeshwari: 1 article (07/2006)|
|9.||Albinescu, Dragos: 1 article (09/2005)|
|10.||Moriarty, Robert M: 1 article (09/2005)|
|1.||Breast Neoplasms (Breast Cancer)
03/01/2006 - "The present study was conducted to determine the effects of 1alpha(OH)D5 on the growth of normal mouse mammary gland and normal-like human breast epithelial MCF-12F cells and to compare these effects with carcinogen-transformed MCF-12F and breast cancer cells. "
01/01/2000 - "In this study, we evaluated the cell-differentiating action of 1alpha(OH)D5 in breast cancer cells. "
05/01/2007 - "Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB231 breast cancer cells responsive to 1alpha-hydroxyvitamin D5."
03/01/2006 - "These results indicate that the growth inhibitory effect of 1alpha(OH)D5 was achieved in both carcinogen-transformed MCF-12F and breast cancer cells at a dose that was non-inhibitory in normal-like breast epithelial cells."
09/16/2005 - "[reaction: see text] 1Alpha-hydroxyvitamin D5 (1) is a promising chemopreventive agent for breast cancer and is being developed as a drug. "
|2.||Prostatic Neoplasms (Prostate Cancer)
01/01/2000 - "UISO-BCA-4 cells pretreated for 10 days in vitro with 1 microM 1alpha(OH)D5 failed to form tumors when transplanted into athymic mice. "
10/01/2004 - "In a 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary carcinogenesis experiment, 1alpha (OH)D5 (40 microg/kg diet) inhibited cancer incidence by 37.5% (p<0.05) if 1alpha (OH)D5 was present in food during the promotion phase (+1 to end). "
|4.||Cholecalciferol (Vitamin D3)
|5.||Calcitriol Receptors (Calcitriol Receptor)
|7.||Steroid Receptors (Steroid Receptor)